Eli Lilly's CFO retiring after 27 years at company; Alexion names a new slate of execs
→ Mina Sooch has resigned as president, CEO, and director of Gemphire, citing “personal reasons.” The company has struggled financially and its drug candidate, gemcabene, in-licensed from Pfizer, has experienced roadblocks that are preventing it from being developed. Pfizer has the right to get the drug back if Gemphire does not succeed in commercializing it. Board member Dr. Steven Gullans will fill the role of president and CEO until the company finds a replacement.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.